TORONTO, July 8, 2014 (GLOBE NEWSWIRE) -- Revive Bioscience states that it will not rescind the Axxess Pharma Inc. Asset Purchase Agreement, following the successful resolution of certain undisclosed and outstanding items. Revive recognizes Axxess Pharma Inc. ownership of the TapouT license, products and related patents. Axxess Pharma Inc. has achieved remarkable strides in the marketing of existing products and the development of a new product line. We clearly see the long-term potential and benefits of our current alliance with Axxess Pharma Inc., and support all of their efforts.
REVIVE SHAREHOLDERS GROUP
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of our financial networking and press release businesses. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with a smaller public company engaged in an industry subject to rapid change. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate.
CONTACT: 647-799-1051Source:Revive BioScience Ltd